Brian A Bergmark, Nicholas A Marston, Thomas A Prohaska, Veronica J Alexander, André Zimerman, Filipe A Moura, Sabina A Murphy, Erica L Goodrich, Shuanglu Zhang, Daniel Gaudet, Ewa Karwatowska-Prokopczuk, Sotirios Tsimikas, Robert P Giugliano, Marc S Sabatine
BACKGROUND: Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3), a genetically validated target for triglyceride lowering. METHODS: In this phase 2b, randomized, controlled trial, we assigned adults either with moderate hypertriglyceridemia (triglyceride level, 150 to 499 mg per deciliter) and elevated cardiovascular risk or with severe hypertriglyceridemia (triglyceride level, ≥500 mg per deciliter) in a 1:1 ratio to either a 50-mg or 80-mg cohort...
April 7, 2024: New England Journal of Medicine